Investor's Business Daily - The biotech said Q4 EPS rose 18% to 73 cents, below analyst views for 75 cents. Sales rose 40% to $1.06 bil, above views. Celgene (NMS:CELG) sees 2011 sales of $4.4 bil-$4.5 bil, up from $3.6 bil in 2010 and above analyst views for $4.2 bil. The company also said data from a late-stage trial showed that its Abraxane breast cancer drug didn't significantly extend survival in lung cancer patients. Shares fell 4.6% to 56.44.
More...
More...